Search | Clinical Trials Finder

Conditions: Cushing's Syndrome
Interventions: Mifepristone; Drug
Lead sponsor: HRA Pharma; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
Interventions: SPI-62, Placebo; Drug
Lead sponsor: Sparrow Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 8
States / cities: Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more

Conditions: Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease, Peutz-Jeghers Syndrome
Interventions: oCRH; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Years to 70 Years
Enrollment: 1,387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Aldosteronism, Hypertension
Interventions: Eplerenone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Hyperaldosteronism
Interventions: Baxdrostat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Los Angeles, California • San Francisco, California • Farmington, Connecticut + 17 more

Conditions: Cushing's Syndrome
Interventions: Cushing's syndrome confirmation; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Escondido, California • Hollywood, Florida • San Antonio, Texas

Conditions: Congenital Adrenal Hyperplasia, Hyperplasia, Adrenal Hyperplasia, Congenital Disorders, Adrenocortical Hyperfunction, Disorders of Sex Development, Urogenital Abnormalities, Genetic Diseases, Inborn, Steroid Metabolic Diseases, Inborn, Adrenal Gland Disease, Hydrocortisone
Interventions: Subcutaneous hydrocortisone; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 4 Years to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension, Mineralocorticoid Excess
Interventions: Eplerenone, Amlodipine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 17 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Aldosteronism, Resistant Hypertension, Secondary Hypertension, Hyperaldosteronism, Mineralocorticoid Excess, Hypertension
Interventions: Best Practice Advisory Computerized Alert; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 12,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypercortisolism, Diabetes Mellitus, Type 2
Interventions: Mifepristone 300 MG [Korlym], Placebo for mifepristone; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 36
States / cities: Escondido, California • Gardena, California • Huntington Park, California + 29 more

Conditions: Healthy, Involutional Depression
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Cushing's Syndrome
Interventions: SOM230 s.c.; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Portland, Oregon + 2 more

Conditions: Hyperaldosteronism, Hypercortisolism, Cushing s Syndrome
Interventions: [68Ga]Ga-PentixaFor; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Adrenal Hyperplasia
Interventions: NBI-77860; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 12 Years to 18 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Seattle, Washington

Conditions: Cushing's Syndrome
Interventions: Treatment of Cushing's; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Cushing's Disease, Cushing's Syndrome
Interventions: Mifepristone; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Hollywood, Florida • Baltimore, Maryland • Ann Arbor, Michigan + 2 more

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 48
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Cushings Disease
Interventions: osilodrostat, LCI699 matching placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 12
States / cities: Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Hyperaldosteronism, Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1981 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cushing Syndrome
Interventions: MUSE biofeedback; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cushing's Syndrome
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
Interventions: Intervention 1: Adrenalectomy, Intervention 2: Semaglutide; Procedure · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Endogenous Cushing Syndrome, Adrenal Insufficiency, Hypercortisolism
Interventions: Osilodrostat; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia

MR Antagonist and LSD1

Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

Dynamics of Leptin and Endocrine Function

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

Effects of Salt Intake on the Nervous Systems of Patients With Salt-Sensitive High Blood Pressure

Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)

Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement